C

CytoTools AG
XETRA:T5O

Watchlist Manager
CytoTools AG
XETRA:T5O
Watchlist
Price: 101.26 EUR 0.98% Market Closed
Market Cap: 52.8m EUR
Have any thoughts about
CytoTools AG?
Write Note

CytoTools AG
Tax Provision

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CytoTools AG
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
C
CytoTools AG
XETRA:T5O
Tax Provision
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Tax Provision
-€255.8m
CAGR 3-Years
N/A
CAGR 5-Years
-203%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Tax Provision
€2.8m
CAGR 3-Years
-66%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Tax Provision
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Tax Provision
€13.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Formycon AG
XETRA:FYB
Tax Provision
-€3.3m
CAGR 3-Years
-238%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CytoTools AG
Glance View

Market Cap
52.8m EUR
Industry
Biotechnology

CytoTools AG is a biotechnology company, which engages in the research and development of therapies to treat cause of diseases. The company is headquartered in Darmstadt, Hessen and currently employs 1 full-time employees. The company went IPO on 2007-05-18. The firm holds interests in research and development (R&D) companies DermaTools Biotech GmbH, which is active in the field of dermatology and urology, and CytoPharma GmbH, which is engaged in product development for cardiovascular diseases, cancer and other indications. CytoTools AG manages the patent portfolio and coordinates the licensing for its subsidiaries. The product pipeline of disease modifying therapies based on the mechanisms of cell growth and programmed cell death, comprising small molecules and biologics across a range of disease indications, includes DermaPro, the Company's lead product indicated for diabetic and venous foot ulcers in phase III of clinical trials, as well as Utisept, an urological medical device for flushing the bladder in urinary tract infections, and pre-clinical stage CardioClean for the treatment of restenosis, diabetis and carotis-stenosis.

T5O Intrinsic Value
151.77 EUR
Undervaluation 33%
Intrinsic Value
Price
C

See Also

Back to Top